Olanzapina y consumo de cocaína en programas de mantenimiento con metadonanuevos resultados

  1. M. Landabaso 1
  2. I. Iraurgi 2
  3. J.M. Jiménez-Lerma 3
  4. J. A. Hormaechea 4
  5. J. Sanz 1
  6. A. Larrazabal 5
  7. A. Aizpuru 1
  8. M. Gutiérrez-Fraile 6
  1. 1 Centro de Drogodependencias de Baracaldo
  2. 2 MAPS Rekalde. Bilbao
  3. 3 CTT-Álava
  4. 4 Aita Menni. Bilbao
  5. 5 CSM Rentería
  6. 6 Hospital de Cruces
    info

    Hospital de Cruces

    Barakaldo, España

    ROR https://ror.org/03nzegx43

Show affiliations +
Journal:
Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica

ISSN: 1134-5934

Year of publication: 2003

Volume: 10

Issue: 5

Pages: 160-164

Type: Article

DIALNET GOOGLE SCHOLAR

More publications in: Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica

Abstract

Objective: To assess the use of olanzapine as a treatment for reduction of cocaine use in a methadone maintenance program (MMP). Patients and method: A Latin-square design was applied to 45 individuals participating in MMPs in three different clinics. Two blocking variables were used: dispensing methadone dose (with three levels: < 59, 60-80 and > 81 mg/day), and the frequency of cocaine consumption in the three months prior to starting treatment (also with three levels: no consumption, < 20% and > 21% in positive urine tests). The independent variable, olanzapine dose (also with three levels: 0.5 and 10 mg/day), was applied in accordance with the protocol design. Patients received olanzapine treatment corresponding to design allotment, together with their daily dose of methadone. The final outcome was the percentage of cocaine consumption estimated by means of urine sample analysis through immunoassay in the three months after starting treatment. A weekly urine sample was taken during this period; 12 samples were taken from 37 patients and 13 samples were taken from 8 patients. Results: Variant analysis through breakdown of the sources of variation typical of Latin-square design revealed a significant effect for therapy (F(2,36) = 17.19; p < 0,001) and for interaction (F(2,36) = 12.47; p < 0,001). The mean percentage of positive urine tests was 22.6% among untreated subjects, 4.2% for those receiving olanzapine treatment at a dose of 5 mg/day and 3.8% among those on 10 mg/day. Conclusions: Olanzapine treatment had a significant effect in reducing cocaine consumption among users taking part in an MMP. Nonetheless, because of the presence of interaction effects, the results should be interpreted with caution and new designs allowing greater control over the effects of the variants involved are required.

Data source: Dialnet